NASDAQ:ONCE Spark Therapeutics (ONCE) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ONCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.18▼$0.1850-Day Range$110.05▼$113.5752-Week Range$34.53▼$114.20VolumeN/AAverage Volume891,560 shsMarket Capitalization$6.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesSocial MediaStock AnalysisHeadlinesSocial Media Get Spark Therapeutics alerts: Email Address Ad Behind the MarketsThe World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!Get the name of the stock here >>> About Spark Therapeutics Stock (NASDAQ:ONCE)Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Read More Ad Behind the MarketsThe World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!Get the name of the stock here >>> ONCE Stock News HeadlinesApril 23, 2024 | uk.news.yahoo.comVoyager 1: NASA's longest-running spacecraft back in touch with Earth after five months of silenceApril 7, 2024 | msn.comTotal eclipse sparks ‘once-in-a-lifetime’ parties across blackout zone: ‘All everyone is talking about’April 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 27, 2024 | mirror.co.ukSharon Osbourne takes another swipe at X Factor as she admits she's 'very much against' rebootMarch 16, 2024 | sg.finance.yahoo.comAries Season Is Here, and It's Time to Start FreshMarch 14, 2024 | finance.yahoo.comful. Health Introduces Innovative Solution to Help Group Health Plans Right-Size Healthcare SpendingMarch 13, 2024 | finance.yahoo.comFred L. Goldenberg: Drug prices out of controlMarch 5, 2024 | finance.yahoo.comOmega Park inaugurates the Makwa Foundation for the Conservation and Protection of Endangered SpeciesApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 28, 2024 | ca.news.yahoo.comViking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.February 27, 2024 | markets.businessinsider.comPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsFebruary 24, 2024 | msn.comBig Money Is Taking Over MDMA-Assisted TherapyFebruary 23, 2024 | finance.yahoo.comPCM Trials Acquires EmVenio Research to Create the Most Patient-Centric Model for Hybrid and Decentralized Clinical TrialsFebruary 22, 2024 | msn.com10 Minor Unsolved Mysteries In The Legend of Zelda With Major ImplicationsFebruary 8, 2024 | msn.comMitochondrial misfire sparks inflammationFebruary 2, 2024 | finance.yahoo.comAgendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®January 29, 2024 | finanznachrichten.deAdverum Biotechnologies, Inc.: Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerJanuary 28, 2024 | msn.comGene therapy for pets: French company buys start-up cofounded by Penn’s Jim WilsonJanuary 26, 2024 | bizjournals.comDr. Carl June on the next biotech breakthroughs and why Philadelphia will lead the wayJanuary 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics on Promising IgAN Drug Trial ResultsJanuary 23, 2024 | uk.finance.yahoo.comLeukemia Therapeutics Market: Robust Growth Expected with Innovative CAR-T TreatmentsJanuary 17, 2024 | finance.yahoo.comAward-Winning Biotech Training Program to Begin Recruitment with New Employer Partner in Life SciencesJanuary 7, 2024 | bizjournals.comAs Philadelphia life sciences projects slow, developers remain bullish on long-term outlookJanuary 2, 2024 | msn.comMicroRNA is the master regulator of the genome − researchers are learning how to treat disease by harnessing the way it controls genesJanuary 1, 2024 | msn.comOpinion: Bringing psychedelic medicine from the margins to the mainstreamDecember 27, 2023 | msn.com'Magical' Theme Park Date Sparks Couple GoalsDecember 26, 2023 | msn.comIn $4 billion deal, Bristol Myers Squibb to buy cancer therapeutics firm RayzeBioSee More Headlines Receive ONCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2018Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONCE CUSIPN/A CIK1609351 Webwww.sparktx.com Phone888-772-7560FaxN/AEmployees368Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,820,000.00 Net Margins-358.41% Pretax MarginN/A Return on Equity-59.10% Return on Assets-33.13% Debt Debt-to-Equity Ratio0.35 Current Ratio4.67 Quick Ratio4.35 Sales & Book Value Annual Sales$64.72 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$13.15 per share Price / Book0.01Miscellaneous Outstanding Shares38,523,000Free FloatN/AMarket Cap$6.94 million OptionableNo Data Beta2.05 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jeffrey D. Marrazzo (Age 40)Co-Founder, CEO & Director Dr. Katherine A. High (Age 67)Co-Founder, Pres, Head of R&D and Director Mr. Stephen W. Webster (Age 58)Chief Financial Officer Mr. Joseph W. La Barge Esq. (Age 48)J.D., Chief Legal Officer & Sec. Mr. Daniel R. Faga (Age 39)Chief Bus. Officer Key CompetitorsTitan PharmaceuticalsNASDAQ:TTNPCreative Medical TechnologyNASDAQ:CELZChromocell TherapeuticsNYSE:CHROSorrento TherapeuticsNASDAQ:SRNEFresh Tracks TherapeuticsNASDAQ:FRTXView All Competitors ONCE Stock Analysis - Frequently Asked Questions How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to analysts' expectations of $29.44 million. Spark Therapeutics had a negative trailing twelve-month return on equity of 59.10% and a negative net margin of 358.41%. What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Pfizer (PFE) and When did Spark Therapeutics IPO? Spark Therapeutics (ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. This page (NASDAQ:ONCE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spark Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
